
HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use NITISINONE CAPSULES safely and effectively. See full prescribing information for NITISINONE CAPSULES.

NITISINONE Capsules, for oral use Initial U.S. Approval: 2002

INDICATIONS AND USAGE Nitisinone is a hydroxy-phenylpyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. (1)

DOSAGE AND ADMINISTRATION
Recommended Dosage (2.1):

- The recommended starting dosage is 0.5 mg/kg orally twice daily.
- In patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum of 4 weeks on a stable dosage of nitisinone, the total daily dose may be given once daily.
- Titrate the dosage based on biochemical and/or clinical response, as described in the full prescribing information.
- The maximum total daily dosage is 2 mg/kg orally.

Administration Instructions (2.2):

- Maintain dietary restriction of tyrosine and phenylalanine
- Take Nitisinone Capsules at least one hour before, or two hours after a meal
- For patients who have difficulties swallowing capsules, the capsules may be opened and the contents suspended in a small amount of water, formula, or applesauce immediately before use.
- ----- DOSAGE FORMS AND STRENGTHS
- Capsules: 2 mg, 5 mg, 10 mg, 20 mg. (3)

----- CONTRAINDICATIONS

None (4)

------ WARNINGS AND PRECAUTIONS

<u>Elevated Plasma Tyrosine Levels, Ocular Symptoms, Developmental Delay and Hyperkeratotic Plaques</u>: Inadequate restriction of tyrosine and phenylalanine intake can lead to elevations in plasma tyrosine, which at levels above 500 micromol/L can result in symptoms, intellectual disability and developmental delay or painful hyperkeratotic plaques on the soles and palms; do not adjust Nitisinone Capsules dosage in order to lower the plasma tyrosine concentration. Obtain slit-lamp examination prior to treatment, regularly during treatment;

- Reexamine patients if symptoms develop or tyrosine levels are > 500 micromol/L. Assess plasma tyrosine levels in patients with an abrupt change in neurologic status. (5.1)
- <u>Leukopenia and Severe Thrombocytopenia</u>: Monitor platelet and white blood cell counts. (5.2)

Most common adverse reactions (>1%) are elevated tyrosine levels, thrombocytopenia, leukopenia, conjunctivitis, corneal opacity, keratitis, photophobia, eye pain, blepharitis, cataracts, granulocytopenia, epistaxis, pruritus, exfoliative dermatitis, dry skin, maculopapular rash and alopecia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Eton Pharmaceuticals, Inc., at 1-855-224-0233 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

- ----- DRUG INTERACTIONS ------
- <u>CYP2C9 Substrates</u>: Increased systemic exposure of these co-administered drugs; reduce the dosage. Additional dosage adjustments may be needed to maintain therapeutic drug concentrations for narrow therapeutic index drugs. (7)
- <u>OAT1/OAT3 Substrates</u>: Increased systemic exposure of these co- administered drugs; monitor for potential adverse reactions. (7)

FULL PRESCRIBING INFORMATION: CONTENTS*

1. INDICATIONS AND USAGE

2. DOSAGE AND ADMINISTRATION

- 2.1. Dosage
- 2.2. Administration Instructions

3. DOSAGE FORMS AND STRENGTHS

4. CONTRAINDICATIONS

5. WARNINGS AND PRECAUTIONS

5.1. Elevated Plasma Tyrosine Levels, Ocular Symptoms, Developmental Delay and Hyperkeratotic Plaques

5.2. Leukopenia and Severe Thrombocytopenia

6. ADVERSE REACTIONS

6.1. Clinical Trials Experience

7. DRUG INTERACTIONS

8. USE IN SPECIFIC POPULATIONS

- 8.1. Pregnancy
- 8.2. Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

10. OVERDOSAGE

11. DESCRIPTION

12. CLINICAL PHARMACOLOGY

- 12.1. Mechanism of Action
- 12.2. Pharmacodynamics
- 12.3. Pharmacokinetics

13. NONCLINICAL TOXICOLOGY

13.1. Carcinogenesis, Mutagenesis, Impairment of Fertility

14.CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1. INDICATIONS AND USAGE

Nitisinone Capsules is indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

2. DOSAGE AND ADMINISTRATION

2.1. Dosage

Starting Dosage

The recommended starting dosage of Nitisinone Capsules is 0.5 mg/kg administered orally twice daily.

Maintenance Regimen

In patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum of 4 weeks on a stable dosage of nitisinone, the total daily dose of Nitisinone Capsules may be given once daily (e.g., 1 to 2 mg/kg once daily) [see Clinical Pharmacology (12.2)].

Dosage Titration

Titrate the dosage in each individual patient based on biochemical and/or clinical response.

- Monitor plasma and/or urine succinylacetone concentrations, liver function parameters and alpha-fetoprotein levels.
- If succinylacetone is still detectable in blood or urine 4 weeks after the start of nitisinone treatment, increase the nitisinone dosage to 0.75 mg/kg twice daily. A maximum total daily dosage of 2 mg/kg may be needed based on the evaluation of all biochemical parameters.
- If the biochemical response is satisfactory (undetectable blood and/or urine succinylacetone), the dosage should be adjusted only according to body weight gain and not according to plasma tyrosine levels.
- During initiation of therapy, when switching from twice daily to once daily dosing, or if there is a deterioration in the patient's condition, it may be necessary to follow all available biochemical parameters more closely (i.e., plasma and/or urine succinylacetone, urine 5- aminolevulinate (ALA) and erythrocyte porphobilinogen (PBG)-synthase activity).
- Maintain plasma tyrosine levels below 500 micromol/L by dietary restriction of tyrosine and phenylalanine intake [see Warnings and Precautions (5.1)]. In patients who develop plasma tyrosine levels above 500 micromol/L, assess dietary tyrosine and phenylalanine intake. Do not adjust the Nitisinone Capsules dosage in order to lower the plasma tyrosine concentration.

2.2. Administration Instructions

Administration of Nitisinone Capsules

- Maintain dietary restriction of tyrosine and phenylalanine when taking Nitisinone Capsules.
- *Capsules*: Take at least one hour before, or two hours after a meal [see Clinical Pharmacology (12.3)]. For patients who have difficulty swallowing the capsules, the capsules may be opened and the contents suspended in a small amount of water, formula or applesauce immediately before use.

3. DOSAGE FORMS AND STRENGTHS

Capsules:

- 2 mg: Size "3" hard gelatin capsules with white opaque cap imprinted with "NIT2" in black, and white opaque body imprinted 'ZN11' in black, filled with white to off-white powder.
- 5 mg: Size "3" hard gelatin capsules with white opaque cap imprinted with "NIT5" in black, and white opaque body imprinted 'ZN12' in black, filled with white to off-white powder.
- 10 mg: Size "3" hard gelatin capsules with white opaque cap imprinted with "NIT10" in black, and white opaque body imprinted 'ZN13' in black, filled with white to off-white powder.
- 20 mg: Size "3" hard gelatin capsules with white opaque cap imprinted with "NIT20" in black, and white opaque body imprinted 'ZN14' in black, filled with white to off-white powder.

4. CONTRAINDICATIONS

None.

5. WARNINGS AND PRECAUTIONS

5.1. Elevated Plasma Tyrosine Levels, Ocular Symptoms, Developmental Delay and Hyperkeratotic Plaques

Nitisinone is an inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme in the tyrosine metabolic pathway [see Clinical Pharmacology (12.1)]. Therefore, treatment with nitisinone may cause an increase in plasma tyrosine levels in patients with HT-1. Maintain concomitant reduction in dietary tyrosine and phenylalanine while on nitisinone treatment. Do not adjust nitisinone dosage in order to lower the plasma tyrosine concentration. Maintain plasma tyrosine levels below 500 micromol/L. Inadequate restriction of tyrosine and phenylalanine intake can lead to elevations in plasma tyrosine levels and levels greater than 500 micromol/L may lead to the following:

- Ocular signs and symptoms including corneal ulcers, corneal opacities, keratitis, conjunctivitis, eye pain, and photophobia have been reported in patients treated with nitisinone [see Adverse Reactions (6.1)]. In a clinical study in a non HT-1 population without dietary restriction and reported tyrosine levels >500 micromol/L both symptomatic and asymptomatic keratopathies have been observed. Therefore, perform a baseline ophthalmologic examination including slit-lamp examination prior to initiating nitisinone treatment and regularly thereafter. Patients who develop photophobia, eye pain, or signs of inflammation such as redness, swelling, or burning of the eyes or tyrosine levels are > 500 micromol/L during treatment with Nitisinone Capsules should undergo slit-lamp reexamination and immediate measurement of the plasma tyrosine concentration.
- Variable degrees of intellectual disability and developmental delay. In patients treated with nitisinone who exhibit an abrupt change in neurologic status, perform a clinical laboratory assessment including plasma tyrosine levels.
- Painful hyperkeratotic plaques on the soles and palms.

In patients with HT-1 treated with dietary restrictions and nitisinone who develop

elevated plasma tyrosine levels, assess dietary tyrosine and phenylalanine intake.

5.2. Leukopenia and Severe Thrombocytopenia

In clinical trials, patients treated with nitisinone and dietary restriction developed transient leukopenia (3%), thrombocytopenia (3%), or both (1.5%) [see Adverse Reactions (6.1)]. No patients developed infections or bleeding as a result of the episodes of leukopenia and thrombocytopenia. Monitor platelet and white blood cell counts during nitisinone therapy.

6. ADVERSE REACTIONS

6.1. Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Nitisinone was studied in one open-label, uncontrolled study of 207 patients with HT-1, ages 0 to 22 years at enrollment (median age 9 months), who were diagnosed with HT-1 by the presence of succinylacetone in the urine or plasma. The starting dose of nitisinone was 0.3 to 0.5 mg/kg twice daily, and the dose was increased in some patients to 1 mg/kg twice daily based on weight, biochemical, and enzyme markers. The recommended starting dosage of nitisinone is 0.5 mg/kg twice daily [see Dosage and Administration (2.1)]. Median duration of treatment was 22 months (range 0.1 to 80 months).

The most serious adverse reactions reported during nitisinone treatment were thrombocytopenia, leukopenia, porphyria, and ocular/visual complaints associated with elevated tyrosine levels [see Warnings and Precautions (5.1, 5.2)]. Fourteen patients experienced ocular/visual events. The duration of the symptoms varied from 5 days to 2 years. Six patients had thrombocytopenia, three of which had platelet counts 30,000/microL or lower. In 4 patients with thrombocytopenia, platelet counts gradually returned to normal (duration up to 47 days) without change in nitisinone dose. No patients developed infections or bleeding as a result of the episodes of leukopenia and thrombocytopenia.

Patients with HT-1 are at increased risk of developing porphyric crises, hepatic neoplasms, and liver failure requiring liver transplantation. These complications of HT-1 were observed in patients treated with nitisinone for a median of 22 months during the clinical trial (liver transplantation 13%, liver failure 7%, malignant hepatic neoplasms 5%, benign hepatic neoplasms 3%, porphyria 1%).

The most common adverse reactions reported in the clinical trial are summarized in Table 1.

TABLE 1 Most Common Adverse Reactions
in Patients with HT-1 Treated with
Nitisinone [*]

Elevated tyrosine levels	>10%	
Leukopenia	3%	

Thrombocytopenia	3%
Conjunctivitis	2%
Corneal opacity	2%
Keratitis	2%
Photophobia	2%
Eye pain	1%
Blepharitis	1%
Cataracts	1%
Granulocytopenia	1%
Epistaxis	1%
Pruritus	1%
Exfoliative dermatitis	1%
Dry skin	1%
Maculopapular rash	1%
Alopecia	1%
* reported in at least 1% of n	ationto

* reported in at least 1% of patients

Adverse reactions reported in less than 1% of the patients, included death, seizure, brain tumor, encephalopathy, hyperkinesia, cyanosis, abdominal pain, diarrhea, enanthema, gastrointestinal hemorrhage, melena, elevated hepatic enzymes, liver enlargement, hypoglycemia, septicemia, and bronchitis.

7. DRUG INTERACTIONS

Nitisinone is a moderate CYP2C9 inhibitor, a weak CYP2E1 inducer and an inhibitor of OAT1/OAT3. Table 2 includes drugs with clinically important drug interactions when administered concomitantly with nitisinone and instructions for preventing or managing them.

Table 2: Clinically Relevant Interactions Affecting Co-AdministeredDrugs

	C9 Substrates (e.g., celecoxib, tolbutamide) or rates with a Narrow Therapeutic Index (e.g., farin)
Clinical Impact	Increased exposure of the co-administered drugs metabolized by CYP2C9 [see Clinical Pharmacology (12.3)].
Intervention	Reduce the dosage of the co-administered drugs metabolized by CYP2C9 drug by half. Additional dosage adjustments may be needed to maintain therapeutic drug concentrations for narrow therapeutic index drugs. See prescribing information for those drugs.
OAT1/OAT3 Su	bstrates (e.g., adefovir, ganciclovir, methotrexate)
Clinical Impact	Increased exposure of the interacting drug [see Clinical Pharmacology (12.3)].
Intervention	Monitor for potential adverse reactions related to the

8. USE IN SPECIFIC POPULATIONS

8.1. Pregnancy

<u>Risk Summary</u>

Limited available data with nitisinone use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. Animal reproduction studies have been conducted for nitisinone. In these studies, nitisinone was administered to mice and rabbits during organogenesis with oral doses of nitisinone up to 20 and 8 times respectively, the recommended initial dose of 1 mg/kg/day. In mice, nitisinone caused incomplete skeletal ossification of fetal bones and decreased pup survival at doses 0.4 times the recommended initial dose and increased gestational length at doses 4 times the recommended initial dose. In rabbits, nitisinone caused maternal toxicity and incomplete skeletal ossification of fetal bones at doses 1.6 times the recommended initial dose in the recommended initial bones at doses 1.6 times the recommended initial dose.

The background risk of major birth defects and miscarriage for the indicated population are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

<u>Data</u>

Animal Data

Reproduction studies have been performed in mice at oral doses of about 0.4, 4 and 20 times the recommended initial dose (1 mg/kg/day) and in rabbits at oral doses of about 1.6, 4 and 8 times the recommended initial dose based on the body surface area. In mice, nitisinone has been shown to cause incomplete skeletal ossification of fetal bones at 0.4, 4 and 20 times the recommended initial dose, increased gestational length at 4 and 20 times the recommended initial dose, and decreased pup survival at 0.4 times the recommended initial dose, and decreased pup survival at 0.4 times the recommended initial dose based on the body surface area. In rabbits, nitisinone caused incomplete skeletal ossification of fetal bones at 1.6, 4 and 8 times the recommended initial dose based on the body surface area.

8.2. Lactation

Risk Summary

There are no data on the presence of nitisinone in human milk, the effects on the breastfed infant, or the effects on milk production. Data suggest that nitisinone is present in rat milk due to findings of ocular toxicity and lower body weight seen in drug naive nursing rat pups. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for nitisinone and any potential adverse effects on the breastfeed infant from nitisinone or from the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of nitisinone have been established in pediatric patients for

the treatment of HT-1 in combination with dietary restriction of tyrosine and phenylalanine. Use of nitisinone in pediatric patients is supported by evidence from one open-label, uncontrolled clinical study conducted in 207 patients with HT-1 ages 0 to 22 years (median age 9 months) [see Clinical Studies (14)].

8.5 Geriatric Use

Clinical studies of nitisinone did not include any subjects aged 65 and over. No pharmacokinetic studies of nitisinone have been performed in geriatric patients. In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in this patient population.

10. OVERDOSAGE

Accidental ingestion of nitisinone by individuals eating normal diets not restricted in tyrosine and phenylalanine will result in elevated tyrosine levels. In healthy subjects given a single 1 mg/kg dose of nitisinone, the plasma tyrosine level reached a maximum of 1200 micromol/L at 48 to 120 hours after dosing. After a washout period of 14 days, the mean value of plasma tyrosine was still 808 micromol/L. Fasted follow-up samples obtained from volunteers several weeks later showed tyrosine values back to normal. There were no reports of changes in vital signs or laboratory data of any clinical significance. One patient reported sensitivity to sunlight. Hyper-tyrosinemia has been reported with nitisinone treatment [see Warnings and Precautions (5.1)].

11. DESCRIPTION

Nitisinone capsules contain nitisinone, which is a 4-hydroxyphenyl-pyruvate dioxygenase inhibitor indicated as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1 (HT-1).

Nitisinone occurs as white to yellowish-white, crystalline powder. It is Freely soluble in Acetone, Ethyl acetate and Methylene chloride. Sparingly soluble in absolute alcohol and practically insoluble in water Chemically, nitisinone is 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, and the structural formula is:




Figure 1. The molecular formula is $C_{14}H_{10}F_3NO_5$ with a relative mass of 329.23

Capsules: Hard, white-opaque capsule, 2 mg, 5 mg, 10 mg, and 20 mg strengths of nitisinone, intended for oral administration. Each capsule contains 2 mg, 5 mg, 10 mg, or 20 mg nitisinone, anhydrous lactose and stearic acid. The capsule shell contains gelatin and titanium dioxide, and the imprinting ink contains black iron oxide, propylene glycol, potassium hydroxide, shellac, and strong ammonia solution.

12. CLINICAL PHARMACOLOGY

12.1. Mechanism of Action

Nitisinone is a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme upstream of fumarylacetoacetate hydrolase (FAH) in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with HT-1, nitisinone prevents the accumulation of the catabolic intermediates maleylacetoacetate and fumarylacetoacetate. In patients with HT-1, these catabolic intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate, which are responsible for the observed liver and kidney toxicity. Succinylacetone can also inhibit the porphyrin synthesis pathway leading to the accumulation of 5-aminolevulinate, a neurotoxin responsible for the porphyric crises characteristic of HT-1.

12.2. Pharmacodynamics

In a clinical study, patients with HT-1 were diagnosed by the presence of succinylacetone in urine or plasma and treated with nitisinone [see Clinical Studies (14)]. In all 186 patients whose urine succinylacetone was measured, the urinary succinylacetone concentration decreased to less than 1 mmol/mol creatinine, the lower limit of quantitation. The median time to normalization of urine succinylacetone was 0.3 months. The probability of recurrence of abnormal values of urine succinylacetone was 1% at a nitisinone concentration of 37 micromol/L (95% confidence interval: 23, 51 micromol/L). In 87% (150/172) of patients whose plasma succinylacetone was measured, the plasma succinylacetone concentration decreased to less than 0.1 micromol/L, the lower limit of quantitation. The median time to normalization decreased to less than 0.1 micromol/L, the lower limit of quantitation. The median time to normalization of plasma succinylacetone was 3.9 months.

In another study comparing two dosing regimens, succinylacetone was measured in urine and/or blood in 16 patients with HT-1 aged 5 years to 24 years. All study patients were on a stable nitisinone daily dosage (0.4 mg/kg/day to 1 mg/kg/day) during both study dosing regimens. After at least 4 weeks of twice daily dosing with nitisinone, both the urine and/or blood succinylacetone concentrations were below the limit of quantitation for the assay. Patients were then switched to once daily dosing with the same total daily dosage of nitisinone and blood and/or urine succinylacetone concentrations remained undetectable when measured following at least 4 weeks of treatment with once daily dosing.

Nitisinone inhibits catabolism of the amino acid tyrosine and can result in elevated plasma levels of tyrosine. Therefore, treatment with nitisinone requires restriction of the dietary intake of tyrosine and phenylalanine to prevent the toxicity associated with elevated plasma levels of tyrosine [see Warnings and Precautions (5.1)].

12.3. Pharmacokinetics

The single-dose pharmacokinetics of nitisinone have been studied for Nitisinone Capsules in healthy adult subjects and the multiple-dose pharmacokinetics have been studied for Nitisinone Capsules in healthy subjects.

Absorption

The pharmacokinetic characteristics following single oral administration of nitisinone 30 mg under fasting conditions are shown in Table 3. The multiple-dose characteristics of nitisinone 80 mg once daily are shown in Table 4. Steady-state (SS) was reached within 14 days dosing in all subjects.

Dose of Nitisinone Under Fasting Conditions					
Treatment	C _{max} (micromol/L) [range]	t _{max} * (h) [range]	AUC _{0-72h} (micromol·h/L) [range]		
Nitisinone Capsule (n=12)	10.5 (26)	3.5 [0.8 to 8.0]	406 (13)		

TABLE 3 Nitisinone Arithmetic Mean (CV%) Pharmacokinetic

Parameters in Healthy Subjects Following a Single Oral 30 mg

* presented as median [range]

TABLE 4 Nitisinone Arithmetic Mean (CV%) Pharmacokinetic Parameters in Healthy Subjects Following Repeated Once Daily Administration of 80 mg Nitisinone Under Fasting Conditions

	C _{max,ss} (micromol/L)	C _{min,ss}) (micromol/L)	t _{max,ss} * (h)	AUC _{0-24h,ss} (micromol·h/L)
Treatment	[CV%]	[range]	[range]	[range]
Nitisinone Capsule (n=18)	120 (23)	73(24)	4.0 [0.0 to 16.0]	2204(18)

* presented as median [range]

Food Effect: No food effect study was conducted with Nitisinone capsules.

Distribution

In vitro binding of nitisinone to human plasma proteins is greater than 95% at 50 micromolar concentration.

Elimination

The mean terminal plasma half-life of single dose nitisinone in healthy male subjects is 54 hours. The mean (CV%) apparent plasma clearance in 18 healthy adults following multiple once daily doses of Nitisinone 80 mg is 113 (16) mL/hr.

Metabolism: In vitro studies have shown that nitisinone is relatively stable in human liver microsomes with minor metabolism possibly mediated by CYP3A4 enzyme.

Excretion: Renal elimination of nitisinone is of minor importance, since the mean of the fraction of dose excreted as unchanged nitisinone in the urine (fe(%)) was 3.0% (n=3) following multiple oral doses of 80 mg daily in healthy subjects. The estimated mean (CV%) renal clearance of nitisinone was 0.003 L/h (25%).

Drug Interaction Studies

Nitisinone does not inhibit CYP2D6. Nitisinone is a moderate inhibitor of CYP2C9, and a weak inducer of CYP2E1 (Table 5). Nitisinone is an inhibitor of OAT1/3 (Table 5).

Table 5. Percent Change in $AUC_{0-\infty}$ and C_{max} for Co-administered Drugs in the Presence of Nitisinone in 18 Healthy Subjects

Drua [*]	Dose of Co-administered Drug (Route of Administration)	Effect of Nitisinone on the Pharmacokinetics of Co-administered Drug [†]		
		AUC _{0-∞}	C _{max}	
CYP2C9 Substrate Tolbutamide [‡]	500 mg (oral)	131% ↑	16% ↑	
CYP2E1 Substrate Chlorzoxazone		27% ↓	18% ↓	
OAT1/3 Substrate Furosemide	20 mg (intravenous)	72% ↑	12% ↑	

- \uparrow = Increased; \downarrow = Decreased
- * The interacting drug was administered alone on Day 1 and together with nitisinone on Day 17.
- + Multiple doses of 80 mg nitisinone were administered daily alone from Day 3 to Day 16.
- ‡ 16 subjects in Period 2 received nitisinone and tolbutamide while 18 subjects in Period 1 received nitisinone alone.

In Vitro Studies Where Drug Interaction Potential Was Not Further Evaluated Clinically

In vitro studies showed that nitisinone does not inhibit CYP1A2, 2C19, or 3A4. Nitisinone does not induce CYP1A2, 2B6 or 3A4/5. Nitisinone does not inhibit P-gp, BCRP, OATP1B1, OATP1B3 and OCT2-mediated transports at therapeutically relevant concentrations.

13. NONCLINICAL TOXICOLOGY

13.1. Carcinogenesis, Mutagenesis, Impairment of Fertility

The carcinogenic potential of nitisinone was assessed in a 26-week oral (gavage) carcinogenicity study in Tg.rasH2 mice. There were no drug-related neoplastic findings in male or female Tg.rasH2 mice at doses up to 100 mg/kg/day nitisinone (approximately 8.1 times the recommended initial dose of 1 mg/kg/day on a body surface area basis).

Nitisinone was not genotoxic in the Ames test and the *in vivo* mouse liver unscheduled DNA synthesis (UDS) test. Nitisinone was mutagenic in the mouse lymphoma cell (L5178Y/TK^{+/-}) forward mutation test and *in vivo* mouse bone marrow micronucleus test.

In a single dose-group study in rats given 100 mg/kg (16.2 times the recommended

initial dose of 1 mg/kg/day on a body surface area basis), reduced litter size, decreased pup weight at birth, and decreased survival of pups after birth was demonstrated.

14.CLINICAL STUDIES

The efficacy and safety of nitisinone in patients with HT-1 was evaluated in one openlabel, uncontrolled study of 207 patients with HT-1, ages 0 to 22 years at enrollment (median age 9 months). Patients were diagnosed with HT-1 by the presence of succinylacetone in the urine or plasma. All patients were treated with nitisinone at a starting dose of 0.3 to 0.5 mg/kg twice daily, and the dose was increased in some patients to 1 mg/kg twice daily based on weight, liver and kidney function tests, platelet count, serum amino acids, urinary phenolic acid, plasma and urine succinylacetone, erythrocyte PBG-synthase, and urine 5-ALA. The median duration of treatment was 22 months (range less than 1 month to 80 months). Efficacy was assessed by comparison of survival and incidence of liver transplant to historical controls.

For patients presenting with HT-1 younger than 2 months of age who were treated with dietary restriction and nitisinone, 2- and 4-year survival probabilities were 88% and 88%, respectively. Data from historical controls showed that patients presenting with HT-1 at younger than 2 months of age and treated with dietary restriction alone had 2- and 4-year survival probabilities of 29% and 29%, respectively. For patients presenting with HT-1 between 2 months and 6 months of age who were treated with dietary restriction and nitisinone, 2- and 4-year survival probabilities were 94% and 94%, respectively. Data for historical controls showed that patients presenting with HT-1 between 2 months and 6 months of presenting with HT-1 between 2 months and 6 months of age treated with dietary restriction alone had 2- and 4-year survival probabilities were 94% and 94%, respectively. Data for historical controls showed that patients presenting with HT-1 between 2 months and 6 months of age treated with dietary restriction alone had 2- and 4-year survival probabilities of 3 months of age treated with dietary restriction alone had 2- and 4-year survival probabilities of 3 months of age treated with dietary restriction alone had 2- and 4-year survival probabilities of 3 months of age treated with dietary restriction alone had 2- and 4-year survival probabilities of 3 months of age treated with dietary restriction alone had 2- and 4-year survival probabilities of 3 months and 6 months of 3 months of 3 months 3 mon

The effects of nitisinone on urine and plasma succinylacetone, porphyrin metabolism, and urinary alpha-1-microglobulin were also assessed in this clinical study.

Porphyria-like crisis were reported in 3 patients (0.3% of cases per year) during the clinical study. This compares to an incidence of 5 to 20% of cases per year expected as part of the natural history of the disorder. An assessment of porphyria-like crises was performed because these events are commonly reported in patients with HT-1 who are not treated with nitisinone.

Urinary alpha-1-microglobulin, a proposed marker of proximal tubular dysfunction, was measured in 100 patients at baseline. The overall median pretreatment level was 4.3 grams/mol creatinine. After one year of treatment in a subgroup of patients (N=100), overall median alpha-1-microglobulin decreased by 1.5 grams/mol creatinine. In patients 24 months of age and younger in whom multiple values were available (N=65), median alpha-1-microglobulin levels decreased from 5.0 to 3.0 grams/mol creatinine (reference value for age less than or equal to 12 grams/mol creatinine). In patients older than 24 months in whom multiple values were available (N=65), median alpha-1-microglobulin levels were available (N=35), median alpha-1-microglobulin levels decreased from 5.0 to 3.0 grams/mol creatinine (reference value for age less than or equal to 12 grams/mol creatinine). In patients older than 24 months in whom multiple values were available (N=35), median alpha-1-microglobulin levels decreased from 2.8 to 2.0 grams/mol creatinine (reference for age less than or equal to 6 grams/mol creatinine).

The long-term effect of nitisinone on hepatic function was not assessed.

16 HOW SUPPLIED/STORAGE AND HANDLING

The capsules are packed in a high density (HD) polyethylene container fitted with 33 mm

Child-Resistant closure. Each bottle contains 60 capsules.

- 2 mg: Size "3" hard gelatin capsules with white opaque cap imprinted with "NIT2" in black, and white opaque body imprinted 'ZN11' in black, filled with white to off-white powder. (NDC 71863-119-60)
- 5 mg: Size "3" hard gelatin capsules with white opaque cap imprinted with "NIT5" in black, and white opaque body imprinted 'ZN12' in black, filled with white to off-white powder. (NDC 71863-120-60)
- 10 mg: Size "3" hard gelatin capsules with white opaque cap imprinted with "NIT10" in black, and white opaque body imprinted 'ZN13' in black, filled with white to off-white powder. (NDC 71863-121-60)
- 20 mg: Size "3" hard gelatin capsules with white opaque cap imprinted with "NIT20" in black, and white opaque body imprinted 'ZN14' in black, filled with white to off-white powder. (NDC 71863-122-60)

Store refrigerated at 2° to 8°C (36° to 46°F) "protect from light". Alternatively, patients/caregivers may store Nitisinone Capsules at room temperature up to 25°C (77°F) for up to 45 days. If not used within 45 days, discard Nitisinone Capsules.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling.

Administration of Nitisinone Capsules

- Maintain dietary restriction of tyrosine and phenylalanine when taking nitisinone.
- *Capsules:* Take at least one hour before, or two hours after a meal. For patients who have difficulty swallowing the capsules, the capsules may be opened and the contents suspended in a small amount of water, formula or applesauce immediately before use.

<u>Elevated Plasma Tyrosine Levels, Ocular Symptoms, Developmental Delay and</u> <u>Hyperkeratotic Plaques</u>

• Inform patients that inadequate restriction may be associated with ocular signs and symptoms, intellectual disability and developmental delay, and painful hyperkeratotic plaques on the soles and palms. Advise patients and caregivers of the need to maintain dietary restriction of tyrosine and phenylalanine and to report any unexplained ocular, neurologic, or other symptoms promptly to their healthcare provider [see Warnings and Precautions (5.1)].

Manufactured by:

M/s Zenara Pharma Private Limited Plot No. 83/B, 84, 87 to 96, Phase III, IDA Cherlapally, Hyderabad, Telangana State - 500051, India (IND)

Manufactured for:

Eton Pharmaceuticals, Inc. Deer Park, IL 60010

Issued: 12/2023

LAB-1497-v2

PRINCIPAL DISPLAY PANEL - 2 mg Capsule Bottle Carton

NDC 71863-119-60

Nitisinone Capsules 2 mg

For Oral Use

60 Capsules




PRINCIPAL DISPLAY PANEL - 5 mg Capsule Bottle Carton

NDC 71863-120-60

Nitisinone Capsules 5 mg

For Oral Use

60 Capsules



PRINCIPAL DISPLAY PANEL - 10 mg Capsule Bottle Carton

NDC 71863-121-60

Nitisinone Capsules 10 mg

For Oral Use

60 Capsules



PRINCIPAL DISPLAY PANEL - 20 mg Capsule Bottle Carton

NDC 71863-122-60

Nitisinone Capsules 20 mg

For Oral Use

60 Capsules



Product Infor	mation						
Product Type		HUMAN PRESCRIP	TION DRUG	ltem	Code (Source)	NDO	C:71863-119
Route of Admini	stration	ORAL					
Active Ingredi	ent/Active	Moiety					
	Ingred	lient Name			Basis of Str	ength	Strength
Nitisinone (UNII: K	5BN214699) (Ni	tisinone - UNII:K5B	N214699)		Nitisinone		2 mg
Inactive Ingre							
Anhydrous Lactos		Ingredient Na	me			Sti	rength
Stearic Acid (UNII:	4ELV7Z 65AP)						
Product Chara	cteristics						
Color	WHIT		Score			no scor	9
Shape 	CAPS	ULE	Size			3mm	
Flavor Contains			Imprint Code				
Packaging							
# Item Code	Pa	ckage Descript	tion	Mar	keting Start Date	Mark	eting End Date
1 NDC:71863-119- 60	1 in 1 CARTON	l	C)1/29/2	024		
1	60 in 1 BOTTL Product	E; Type 0: Not a C	ombination				
Marketing	Informat	ion					
Marketing Category	Applica	tion Number or Citation	Monograph	M	arketing Start Date	Mar	keting End Date
	ANDA21620	1		01/2	9/2024		

NITISINONE			
nitisinone capsule			
Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71863-120

Active Ingredie	ent/Ac [.]	tive Moiety					
	In	gredient Name			Basis of Str	ength	Strength
Nitisinone (UNII: K5	BN21469	99) (Nitisinone - UNII:K5B	N214699)		Nitisinone		5 mg
Inactive Ingree	dients						
		Ingredient Na	me			St	rength
Anhydrous Lactose	e (UNII: 3	SY5LH9PMK)					
Stearic Acid (UNII: 4	4ELV7Z6	5AP)					
Product Chara	cterist	tics					
Color WHITE Score						no scor	e
Shape		CAPSULE	Size		3mm		
Flavor			Imprint Code				
Contains							
Packaging							
# Item Code		Package Descript	tion	Ма	rketing Start Date	Mark	eting End Date
1 NDC:71863-120- 60	1 in 1 C/	ARTON		01/29/	2024		
1	60 in 1 E Product	BOTTLE; Type 0: Not a C	ombination				
Marketing I	nforr	nation					
_			Managura		la ukatin a Ctart	N 4	leating First
Marketing Category	Ар	plication Number or Citation	Monograph	M	larketing Start Date	Mar	keting End Date
ANDA	ANDAZ	216201		01/	29/2024		

	NITISINON	E
--	-----------	---

nitisinone capsule

Product Information						
Product Type	HUMAN PRESCRIPTION DRUG	ltem Code	(Source) N	IDC:71863-121		
Route of Administration	ORAL					
Active Ingredient/Active Moiety						
Ingred	ient Name	Basi	is of Strength	Strength		
Nitisinone (UNII: K5BN214699) (Ni	Nitis ino	ne	10 mg			

In	active Ingre	dients					
			Ingredie	ent Nar	me		Strength
An	hydrous Lactos	e (UNII: 3	SY5LH9PMK)				
Ste	earic Acid (UNII:	4ELV7Z6	5AP)				
Pr	roduct Chara	cteris	tics				
Co	lor		WHITE		Score		no score
Sh	аре		CAPSULE		Size		3mm
Fla	avor				Imprint Cod	e	
Со	ontains						
Pa	ackaging						
	ackaging Item Code		Package D	escript	tion	Marketing Start Date	Marketing End Date
#		1 in 1 C/	-)escript			
#	Item Code NDC:71863-121-		-	-		Date	Marketing End Date
# 1	Item Code NDC:71863-121-	60 in 1 E	ARTON	-		Date	-
# 1 1	Item Code NDC:71863-121- 60	60 in 1 E Product	ARTON BOTTLE; Type 0:	-		Date	-
# 1 1	Item Code	60 in 1 E Product	ARTON BOTTLE; Type 0: Mation	: Not a Co	ombination	Date 01/29/2024	Date
# 1 1	Item Code NDC:71863-121- 60	60 in 1 E Product	ARTON BOTTLE; Type 0: mation plication Num	: Not a Co	ombination	Date	Date

NITISINONE					
nitisinone capsule					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	ltem	Code (Source	e)	NDC:71863-122
Route of Administration	ORAL				
Active Ingredient/Active	Maiatu				
	•				
Ingred	ient Name		Basis of St	rengt	th Strength
Nitisinone (UNII: K5BN214699) (Ni	Nitisinone (UNII: K5BN214699) (Nitisinone - UNII:K5BN214699)				20 mg
Inactive Ingredients					
Ingredient Name					Strength
Anhydrous Lactose (UNII: 3SY5LF	19РМК)				
Stearic Acid (UNII: 4ELV7Z65AP)					

Product Chara	cteristics				
Color	WHITE	WHITE Score			
Shape	CAPSULE	Size		3mm	
Flavor		Imprint Code			
Contains					
Dockoging					
Packaging					
# Item Code	Package De	scription	Marketing Start Date	Marketing End Date	
1 NDC:71863-122- 60	1 in 1 CARTON	C	01/29/2024		
1	60 in 1 BOTTLE; Type 0: Not a Combination Product				
Markoting	nformation				
	nformation			Marketing End	
Marketing Category		plication Number or Monograph Marketing Star Citation Date			
			01/29/2024		

Labeler - Eton Pharmaceuticals, Inc. (080870465)

_ _ _ _ _

Establishment				
Name	Address	ID/FEI	Business Operations	
Zenara Pharma Private Limited		924839850	MANUFACTURE(71863-119, 71863-120, 71863-121, 71863-122) , PACK(71863-119, 71863-120, 71863-121, 71863-122)	
Establishme	nt			

Name	Address	ID/FEI	Business Operations
Sionc Pharmaceuticals Pvt. Ltd		864354620	API MANUFACTURE(71863-119, 71863-120, 71863-121, 71863- 122)

Establishment					
Name	Address	ID/FEI	Business Operations		
Teena Biolabs Private Limited		650690048	ANALYSIS(71863-119, 71863-120, 71863-121, 71863-122)		

Establishment					
Name	Address	ID/FEI	Business Operations		
Energon Labs Private Limited		861446182	ANALYSIS(71863-119, 71863-120, 71863-121, 71863-122)		

Establishment						
Name	Address	ID/FEI	Business Operations			
Choksi Laboratorties Limited		854220481	ANALYSIS(71863-119, 71863-120, 71863-121, 71863-122)			

Revised: 2/2024